Researchers Engineered New Immortalized Liver Cell Lines
The IL-HEP1 and IL-HEP2 models offer a more stable platform for toxicology and drug metabolism studies.
Updated on Sept. 25, 2026 in Life Sciences
Live Poll
Do you believe new laboratory cell models improve the reliability of medical research?
Researchers have created two immortalized non-cancer human hepatocyte cell lines, IL-HEP1 and IL-HEP2, to overcome the limitations of primary cells and cancer-derived lines. These research-stage cell lines are designed to provide more consistent performance in pharmacological and metabolic investigations.
Why it matters
Primary human liver cells often lose function quickly, while cancer-derived models frequently exhibit metabolic abnormalities that skew data. These new lines aim to provide a more reliable, stable platform for testing drug toxicity and regenerative medicine applications.
The researchers achieved CYP2C9 activity exceeding that of HepG2 cells, though CYP3A4 activity reached only 45-50% of HepG2 levels. These lines were generated by transfecting hepatocytes with SV40 large T antigen and human telomerase reverse transcriptase.
The details
To extend the proliferative lifespan of the hepatocytes, the researchers introduced SV40 large T antigen—a viral protein that forces cell division—and human telomerase reverse transcriptase, an enzyme that prevents the erosion of chromosome ends. Unlike existing cancer-derived lines, the IL-HEP models maintained contact inhibition, where cells stop dividing upon physical touch, and retained normal epithelial morphology. Functional assays confirmed the cells reliably secrete albumin and express enzymes critical for drug metabolism.
Timeline
September 25, 2026: Article publication date.
The Tech Race
The development of IL-HEP1 and IL-HEP2 aims to improve upon the gold-standard HepG2 hepatoblastoma cells often used in metabolic studies. By providing a non-cancerous alternative, these lines seek to address the metabolic biases inherent in using tumor-derived models for toxicity testing.
These cell lines are research-stage tools intended for use by laboratories involved in pharmacology, toxicology, and drug development. Their implementation may eventually accelerate the drug approval process by providing more predictive, standardized models for assessing liver-related side effects.
The takeaway
The IL-HEP models address a critical bottleneck in hepatic research by balancing proliferative longevity with physiological relevance. Interested researchers should monitor future validation studies that compare the drug-metabolism sensitivity of these lines against primary human cells.
Further reading
For broader developments in cellular modeling, visit our Life Sciences section.
More information
Access the complete peer-reviewed research article for detailed metabolic data and methodology.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe new laboratory cell models improve the reliability of medical research?
